Replacement Investigator Sample Clauses

Replacement Investigator. Should the Investigator terminate his or her affiliation with Institution before this period has expired, Institution shall nominate another person in writing to Sponsor to be responsible for maintenance of the Clinical Trial Records. Sponsor shall have the right to approve or deny the nominated replacement person.
Sample 1
AutoNDA by SimpleDocs
Replacement Investigator. If Investigator ceases to be on the medical staff of Institution or can no longer serve as Investigator, Institution and Investigator shall notify Sponsor in writing within ten (10) days and propose a substitute investigator. Sponsor shall notify Institution promptly of its decision either to continue the Study with the substitute principal investigator or to terminate the Study. In the event of continuation, the substitute investigator shall sign a contract amendment provided by Sponsor acknowledging his or her new duties as Investigator. Sponsor reserves the right to terminate or replace the Investigator if there is information available to Sponsor indicating that:
Sample 1
Replacement Investigator. If Investigator ceases to be on the medical staff of Institution or can no longer serve as Investigator, Institution and Investigator shall notify Sponsor in writing within ten (10) days and propose a substitute investigator. Sponsor shall notify Institution promptly of its decision either to continue the Study with the substitute principal investigator or to terminate the Study. In the event of continuation, the substitute investigator shall sign a contract amendment provided by Sponsor acknowledging his or her new duties as Investigator. Sponsor reserves the right to terminate or replace the Investigator if there is information available to Sponsor indicating that: (i) the Investigator has failed to perform his/her obligations or has breached the Agreement; (ii) Investigator has repeatedly or deliberately failed to comply with the requirements of any authority; or (iii) Investigator has submitted false information to Sponsor, another sponsor/client, or any authority or notified body. Institution and Sponsor shall diligently and cooperatively attempt to identify a replacement for Investigator that is acceptable to Sponsor. The replacement Investigator shall be a Party to this Agreement in the same manner as was the original Investigator. The substitution of an Investigator (“Replaced Investigator”) shall not affect the obligations of the remaining, non-substituted parties to this Agreement. Upon substitution, the survival provision set forth in Section below shall apply to the Replaced Investigator, provided that such Replaced Investigator shall no longer have any rights to publish as provided herein. 1.12. V
Sample 1

Related to Replacement Investigator

  • Investigator Where a difference arises between the parties relating to the dismissal, discipline or suspension of an employee, or to the interpretation, application, operation or alleged violation of this agreement, including any questions as to whether a matter is arbitrable, during the term of the collective agreement, an arbitrator agreed to by the parties shall, at the request of either party:

  • Principal Investigator The research will be under the direction of (“Principal Investigator”). If, for any reason, he/she is unable to continue to serve as Principal Investigator and a successor acceptable to both UHD and Sponsor is not available, this Agreement shall be terminated as provided in Section 7.

  • Office of Inspector General Investigative Findings Expert Review In accordance with Senate Bill 799, Acts 2021, 87th Leg., R.S., if Texas Government Code, Section 531.102(m-1)(2) is applicable to this Contract, Contractor affirms that it possesses the necessary occupational licenses and experience.

  • Independent Investigation Subscriber, in making the decision to purchase the Units, has relied upon an independent investigation of the Company and has not relied upon any information or representations made by any third parties or upon any oral or written representations or assurances from the Company, its officers, directors or employees or any other representatives or agents of the Company, other than as set forth in this Agreement. Subscriber is familiar with the business, operations and financial condition of the Company and has had an opportunity to ask questions of, and receive answers from the Company’s officers and directors concerning the Company and the terms and conditions of the offering of the Units and has had full access to such other information concerning the Company as Subscriber has requested. Subscriber confirms that all documents that it has requested have been made available and that Subscriber has been supplied with all of the additional information concerning this investment which Subscriber has requested.

  • Submitting Investigator An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000178 : The Cancer Genome Atlas (TCGA) Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above.

  • Certification for Federal-Aid Contracts Lobbying Activities A. The CONSULTANT certifies, by signing and submitting this Contract, to the best of its knowledge and belief after diligent inquiry, and other than as disclosed in writing to the LPA prior to or contemporaneously with the execution and delivery of this Contract by the CONSULTANT, the CONSULTANT has complied with Section 1352, Title 31, U.S. Code, and specifically, that:

  • Institution and Investigator acknowledge that SPONSOR has no obligation to indemnify or be responsible for any loss, claim, cost (including reasonable attorney fees) or demand if and to the extent such losses, claims or demands arise from any injuries or damages resulting from Institution’s, Investigator’s or the Study Personnel’s negligence, breach of this Agreement, failure to adhere to the Protocol, failure to obtain signed informed consent forms, failure to follow Applicable Law, misuse of the Study Drug, unauthorized warranties, or willful misconduct. This indemnification obligation is without prejudice to the precedence of insurance coverage from compulsory clinical trial insurance. 12.3. Zdravotnické zařízení a zkoušející berou na vědomí, že ZADAVATEL nevyplatí žádné odškodnění ani není odpovědný za žádné ztráty, náklady, spory (včetně přiměřených nákladů na právní pomoc) či nároky v souvislosti s újmou či škodou, ke kterým došlo v důsledku nedbalosti na straně zdravotnického zařízení, zkoušejícího a/nebo členů týmu provádějícího klinické hodnocení a/nebo v důsledku toho, že zdravotnické zařízení, zkoušející a/nebo některý člen týmu provádějícího klinické hodnocení porušili ustanovení této smlouvy, porušili ustanovení protokolu, nenechali subjekt hodnocení podepsat informovaný souhlas, porušili ustanovení platných zákonů, chybným způsobem použili studijní léčivo ZADAVATELe, způsobili škodu úmyslným zaviněním a/nebo poskytli neoprávněné záruky. Touto povinností odškodnění není dotčeno přednostní pojistné krytí z povinného pojištění klinického hodnocení.

  • Geotechnical Investigation Perform in accordance with the City Design Manual and other City requirements as designated in writing by the Director.

  • Formal Investigation Once the matter has been brought to the attention of the Store executive, an internal investigation of the complaint will be conducted at which time the complainant will be requested to present, in writing, the particulars of the harassment. Such internal investigation will be initiated no later than ten (10) business days of the matter being brought to the attention of the Store executive, and shall be concluded no later than thirty (30) business days of the initiation of the investigation. Any extension of the aforementioned time frames must have the agreement of the complainant and the union if the complainant has chosen to involve it. Based on the outcome of the investigation, which will be provided in writing upon the completion of the investigation, to both the complainant and the union, should the complainant consent to this disclosure, it will be determined if there has been a breach of Company policy on harassment, and the appropriate action will be taken in the event that harassment is determined to have occurred. STEP THREE - SUBSEQUENT INCIDENTS Subsequent incidents should immediately be reported and followed by a written description to the most senior store executive involved in Step Two for further investigation and disciplinary action, if confirmed, with a copy to the union Chairperson with the consent of the complainant. After all steps of the Harassment Protection Policy have been exhausted, if the incident has not been resolved to the satisfaction of the employee, the employee may file a grievance at Step 2 of the grievance procedure.

  • Accident Investigation All accidents resulting in a fatality or injury requiring medical treatment will be investigated by one representative of the IBEW and one representative of the Employer. The accident investigation report will be submitted to:

Time is Money Join Law Insider Premium to draft better contracts faster.